A Pharmacokinetic Overview of Nanotechnology-Based Drug Delivery Systems: An ADME-Oriented Approach

Critical Reviews in Therapeutic Drug Carrier Systems

Volumn 30, Issue 5, 2013, Pages 435-467

  Hamidi, Mehrdad ^a,b   Azadi, Amir ^c   Rafiei, Pedram ^d   Ashrafi, Hajar ^e  

^a ZANJAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b ZANJAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d UNIVERSITY OF SASKATCHEWAN   (Canada)

^e SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Drug delivery; Nanocarriers; Nanotechnology; Pharmacokinetic

Indexed keywords

AMPHOTERICIN B CHOLESTEROL SULFATE; AMPHOTERICIN B LIPID COMPLEX; APOLIPOPROTEIN B; APOLIPOPROTEIN E; APREPITANT; ASPARAGINASE; ASPARAGINASE MACROGOL; ASTODRIMER; AURIMUNE; CURCUMIN; CYCLODEXTRIN; CYTARABINE; DAUNORUBICIN; DOXORUBICIN; ESTRADIOL; FENOFIBRATE; FUSED IN SARCOMA PROTEIN; GLATIRAMER; HEPATITIS A VACCINE; IRON OXIDE; LIPOSOME; LOW DENSITY LIPOPROTEIN; MEGESTROL ACETATE; PACLITAXEL; PEGADEMASE; PEGAPTANIB; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; PEGVISOMANT; PERFLUTREN; PROPOFOL; RAPAMYCIN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; TUMOR NECROSIS FACTOR ALPHA; ULTRASMALL SUPERPARAMAGNETIC IRON OXIDE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN;

ARTICLE; ASEPTIC MENINGITIS; BLOOD PLACENTA BARRIER; BREAST CANCER; DRUG ABSORPTION; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG EXCRETION; DRUG METABOLISM; DRUG RELEASE; DRUG SAFETY; ENZYME REPLACEMENT; FEBRILE NEUTROPENIA; GASTROINTESTINAL TRACT; HEPATITIS A; HEPATITIS C; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HOT FLUSH; HUMAN; INHALATION; KAPOSI SARCOMA; LEUKEMIA; LUNG CANCER; MACROPHAGE; MICROMETASTASIS; MULTIPLE SCLEROSIS; MYCOSIS; NANOTECHNOLOGY; NAUSEA; NEOPLASM; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OPSONIZATION; OVARY CANCER; PHYSICAL CHEMISTRY; RESPIRATORY SYSTEM; RETINA MACULA DEGENERATION; SKIN ABSORPTION; SOLID TUMOR;

ABSORPTION; ANIMALS; BIOTRANSFORMATION; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; HUMANS; NANOSTRUCTURES; NANOTECHNOLOGY; PHARMACEUTICAL PREPARATIONS; PHARMACOKINETICS; TISSUE DISTRIBUTION;

EID: 84885065336     PISSN: 07434863     EISSN: 2162660X     Source Type: Journal    
DOI: 10.1615/CritRevTherDrugCarrierSyst.2013007419     Document Type: Article

References (142)

1. Celia C, Cosco D, Paolino D, Fresta M. Gemcitabine-loaded innovative nanocarriers vs GEMZAR: Biodistribution, pharmacokinetic features and in vivo antitumor activity. Expert Opin Drug Deliv. 2011;8(12):1609-29.
2. Florence AT. "Targeting" nanoparticles: the constraints of physical laws and physical barriers. J Control Release. 2012;164(2):115-24.
3. Mahapatro A, Singh DK. Biodegradable nanoparticles are excellent vehicle for site directed in-vivo delivery of drugs and vaccines. J Nanobiotechnology. 2011;9(1):55.
4. Musthaba SM, Ahmad S, Ahuja A, Ali J, Baboota S. Nano approaches to enhance pharmacokinetic and pharmacodynamic activity of plant origin drugs. Curr Nanosci. 2009;5(3):344-52.
5. Li M, Al-Jamal KT, Kostarelos K, Reineke J. Physiologically based pharmacokinetic modeling of nanoparticles. ACS Nano. 2010;4(11):6303-17.
6. Oberdörster G. Safety assessment for nanotechnology and nanomedicine: concepts of nanotoxicology. J Intern Med. 2010;267(1):89-105.
7. Yang RSH, Chang LW, Yang CS, Lin P. Pharmacokinetics and physiologically-based pharmacokinetic modeling of nanoparticles. J Nanosci Nanotechnol. 2010;10(12):8482-90.
8. Moghimi SM, Hunter AC, Murray JC. Long-circulating and target-specific nanoparticles: theory to practice. Pharmacol Rev. 2001;53(2):283-318.
9. Arias JL, Gallardo V, Ruiz MA. Multifunctional anticancer nanomedicine based on a magnetically responsive cyanoacrylate polymer. Methods Enzymol. 2012;508:61-88.
10. Gao S, Sun J, Fu D, Zhao H, Lan M, Gao F. Preparation, characterization and pharmacokinetic studies of tacrolimus-dimethyl-β-cyclodextrin inclusion complex-loaded albumin nanoparticles. Int J Pharm. 2012;427(2):410-6.
11. Winkler J. Nanomedicines based on recombinant fusion proteins for targeting therapeutic siRNA oligonucleotides. Ther Deliv. 2011;7(2):891-905.
12. Yuan X, Naguib S, Wu Z. Recent advances of siRNA delivery by nanoparticles. Expert Opin Drug Deliv. 2011;8(4):521-36.
13. Wijagkanalan W, Kawakami S, Hashida M. Designing dendrimers for drug delivery and imaging: pharmacokinetic considerations. Pharm Res. 2011;28(7):1500-19.
14. Kaminskas LM, Porter CJH. Targeting the lymphatics using dendritic polymers (dendrimers). Adv Drug Deliv Rev. 2011;63(10-11):890-900.
15. Soppimath KS, Aminabhavi TM, Kulkarni AR, Rudzinski WE. Biodegradable polymeric nanoparticles as drug delivery devices. J Control Release. 2001;70(1):1-20.
16. Vinogradov SV, Bronich TK, Kabanov AV. Nanosized cationic hydrogels for drug delivery: preparation, properties and interactions with cells. Adv Drug Deliv Rev. 2002;54(1):135-47.
17. Hall JB, Dobrovolskaia MA, Patri AK, McNeil SE. Characterization of nanoparticles for therapeutics. Nanomedicine. 2007;2(6):789-803.
18. US Food and Drug Administration. CBER/CDER Guidance for industry: Developing medical imaging drug and biological products part 1: conducting safety assessments. Rockville (MD): US Food and Drug Administration; 2004.
19. US Food and Drug Administration. CDER/CBER Guidance for industry ICH S6: Preclinical safety evaluation of biotechnology-derived pharmaceuticals. Rockville (MD): US Food and Drug Administration; 1997.
20. US Food and Drug Administration. CDER ICH Guidance for industry ICH S8: Immunotoxicity studies for human pharmaceuticals. Rockville (MD): US Food and Drug Administration; 2006.
21. Patri AK DM, Stern ST, McNeil SE. Preclinical characterization of engineered nanoparticles intended for cancer therapeutics. In: Amiji MM, editor. Nanotechnology for cancer therapy. Boca Raton (FL): CRC Press; 2007.
22. Olson H, Betton G, Robinson D, Thomas K, Monro A, Kolaja G, Lilly P, Sanders J, Sipes G, Bracken W, Concordance of the toxicity of pharmaceuticals in humans and in animals. Regul Toxicol Pharmacol. 2000;32(1):56-67.
23. Bimbo LM, Peltonen L, Hirvonen J, Santos HA. Toxicological profile of therapeutic nanodelivery systems. Curr Drug Metab. 2012;13(8):1068-86.
24. Ghaderi S, Ramesh B, Seifalian AM. Fluorescence nanoparticles "quantum dots" as drug delivery system and their toxicity: a review. J Drug Deliv. 2011;19(7):475-86.
25. Chithrani BD, Ghazani AA, Chan WCW. Determining the size and shape dependence of gold nanoparticle uptake into mammalian cells. Nano Lett. 2006;6(4):662-8.
26. Hardman R. A toxicologic review of quantum dots: toxicity depends on physicochemical and environmental factors. Environ Health Perspect. 2006;114(2):165.
27. Decuzzi P, Ferrari M. The adhesive strength of non-spherical particles mediated by specific interactions. Biomaterials. 2006;27(30):5307-14.
28. Moghimi SM, Hunter AC, Murray JC. Nanomedicine: current status and future prospects. FASEB J. 2005;19(3):311-30.
29. Fischer HC, Chan WCW. Nanotoxicity: the growing need for in vivo study. Curr Opin Biotechnol. 2007;18(6):565-71.
30. Wang J, Chen J, Ye N, Luo Z, Lai W, Cai X, Lin Y. Absorption, pharmacokinetics and disposition properties of solid lipid nanoparticles (SLNs). Curr Drug Metab. 2012;13(4):447-56.
31. Nekkanti V, Venkateswarlu V, Akhter Ansari K, Pillai R. Development and pharmacological evaluation of a PEG based nanoparticulate camptothecin analog for oral administration. Curr Drug Deliv. 2011;8(6):661-6.
32. Patel PA, Patravale VB. AmbiOnp: solid lipid nanoparticles of amphotericin B for oral administration. J Biomed Nanotechnol. 2011;7(5):632-9.
33. Fujii Y, Kanamaru T, Kikuchi H, Nakagami H, Yamashita S, Akashi M, Sakuma S. Improvement of low bioavailability of a novel factor Xa inhibitor through formulation of cationic additives in its oral dosage form. Int J Pharm. 2011;421(2):244-51.
34. Morgen M, Bloom C, Beyerinck R, Bello A, Song W, Wilkinson K, Steenwyk R, S Shamblin. Polymeric nanoparticles for increased oral bioavailability and rapid absorption using celecoxib as a model of a low-solubility, high-permeability drug. Pharm Res. 2012:1-14.
35. Parveen R, Baboota S, Ali J, Ahuja A, Vasudev SS, Ahmad S. Oil based nanocarrier for improved oral delivery of silymarin: In vitro and in vivo studies. Int J Pharm. 2011;413(1-2):245-53.
36. Florence AT. Nanoparticle uptake by the oral route: fulfilling its potential? Drug Discov Today Technol. 2005;2(1):75-81.
37. Janes KA, Fresneau MP, Marazuela A, Fabra A, Alonso MJ. Chitosan nanoparticles as delivery systems for doxorubicin. J Control Release. 2001;73(2):255-67.
38. Jani P, Halbert GW, Langridge J, Florence AT. Nanoparticle uptake by the rat gastrointestinal mucosa: quantitation and particle size dependency. J Pharm Pharmacol. 1990;42(12):821-6.
39. Desai MP, Labhasetwar V, Amidon GL, Levy RJ. Gastrointestinal uptake of biodegradable microparticles: effect of particle size. Pharm Res. 1996;13(12):1838-45.
40. Lazzari S, Moscatelli D, Codari F, Salmona M, Morbidelli M, Diomede L. Colloidal stability of polymeric nanoparticles in biological fluids. J Nanopart Res. 2012;14:920-30.
41. Roger E, Lagarce F, Benoit J-P. The gastrointestinal stability of lipid nanocapsules. Int J Pharm. 2009;379:260-5.
42. Hagens WI, Oomen AG, De Jong WH, Cassee FR, Sips AJAM. What do we (need to) know about the kinetic properties of nanoparticles in the body? Regul Toxicol Pharmacol. 2007;49(3):217-29.
43. Maynard AD, Kuempel ED. Airborne nanostructured particles and occupational health. J Nanopart Res. 2005;7(6):587-614.
44. Pilcer G, Amighi K. Formulation strategy and use of excipients in pulmonary drug delivery. Int J Pharm. 2010;392:1-19.
45. Nemmar A, Hoet PHM, Vanquickenborne B, Dinsdale D, Thomeer M, Hoylaerts MF, Vanbilloen H, Mortelmans L, Nemery B, Passage of inhaled particles into the blood circulation in humans. Circulation. 2002;105(4):411-4.
46. Oberdörster G, Elder A. Metal particles and extrapulmonary transport: Oberdörster and Elder respond. Environ Health Perspect. 2007;115(2):A70.
47. Seju U, Kumar A, Sawant KK. Development and evaluation of olanzapine-loaded PLGA nanoparticles for nose-to-brain delivery: in vitro and in vivo studies. Acta Biomater. 2011;7(12):4169-76.
48. Oberdörster G, Sharp Z, Atudorei V, Elder A, Gelein R, Kreyling W, Cox C. Translocation of inhaled ultrafine particles to the brain. Inhal Toxicol. 2004;16(6-7):437-45.
49. Reger MA, Watson GS, Green PS, Baker LD, Cholerton B, Fishel MA, Plymate SR, Cherrier MM, Schellenberg GD, Frey Ii WH. Intranasal insulin administration dose-dependently modulates verbal memory and plasma amyloid-β in memory-impaired older adults. J Alzheimers Dis. 2008;13(3):323-31.
50. Hanson LR, Roeytenberg A, Martinez PM, Coppes VG, Sweet DC, Rao RJ, Marti DL, Hoekman JD, Matthews R B, Frey Ii WH. Intranasal deferoxamine provides increased brain exposure and significant protection in rat ischemic stroke. J Pharmacol Exper Therapeut. 2009;330(3):679-86.
51. Howe HA, Bodian D. Portals of entry of poliomyelitis virus in the chimpanzee. Proc Soc Exp Biol Med. 1940;43:718-21.
52. Elder A, Gelein R, Silva V, Feikert T, Opanashuk L, Carter J, Potter R, Maynard A, Ito Y, Finkelstein J. Translocation of inhaled ultrafine manganese oxide particles to the central nervous system. Environ Health Perspect. 2006;114(8):1172.
53. Jenning V, Gysler A, Schafer-Korting M, Gohla SH. Vitamin A loaded solid lipid nanoparticles for topical use: occlusive properties and drug targeting to the upper skin. Eur J Pharm Biopharm. 2000;49(3):211-8.
54. Müller RH, Dingler A. The next generation after the liposomes: solid lipid nanoparticles (SLN, Lipopearls) as dermal carrier in cosmetics. Eurocosmetics. 1998;7(8):19-26.
55. Oberdörster G, Oberdörster E, Oberdörster J. Nanotoxicology: an emerging discipline evolving from studies of ultrafine particles. Environ Health Perspect. 2005;113(7):823.
56. Curtis J, Greenberg M, Kester J, Phillips S, Krieger G. Nanotechnology and nanotoxicology: a primer for clinicians. Toxicol Rev. 2006;25(4):245-60.
57. Lanone S, Boczkowski J. Biomedical applications and potential health risks of nanomaterials: molecular mechanisms. Curr Mol Med. 2006;6(6):651.
58. Gwinn MR, Vallyathan V. Nanoparticles: health effects-pros and cons. Environ Health Perspect. 2006;114(12):1818.
59. Tinkle SS, Antonini JM, Rich BA, Roberts JR, Salmen R, DePree K, Adkins EJ. Skin as a route of exposure and sensitization in chronic beryllium disease. Environ Health Perspect. 2003;111(9):1202.
60. Rouse JG, Yang J, Ryman-Rasmussen JP, Barron AR, Monteiro-Riviere NA. Effects of mechanical flexion on the penetration of fullerene amino acid-derivatized peptide nanoparticles through skin. Nano Lett. 2007;7(1):155-60.
61. Kohli AK, Alpar HO. Potential use of nanoparticles for transcutaneous vaccine delivery: effect of particle size and charge. Int J Pharm. 2004;275(1):13-7.
62. Ryman-Rasmussen JP, Riviere JE, Monteiro-Riviere NA. Penetration of intact skin by quantum dots with diverse physicochemical properties. Toxicol Sci. 2006;91(1):159-65.
63. 14C-savoxepine loaded poly (D, L-lactic acid) nanospheres to rats. J Control Release. 1994;29:97-104.
64. Wei X-L, Han Y-R, Quan L-H, Liu C-Y, Liao Y-H. Oily nanosuspension for long-acting intramuscular delivery of curcumin didecanoate prodrug: preparation, characterization and in vivo evaluation. Eur J Pharm Sci. 2013;49:286-93.
65. Fu C, Liu T, Li L, Liu H, Chen D, Tang F. The absorption, distribution, excretion and toxicity of mesoporous silica nanoparticles in mice following different exposure routes. Biomaterials. 2013;34:2565-75.
66. Oussoren C, Storm G. Liposomes to target the lymphatics by subcutaneous administration. Adv Drug Deliv Rev. 2001;50:143-56.
67. Corvo MLs, Boerman OC, Oyen WJG, Jorge JoCS, Cruz MEnM, Crommelin DJA, Storm G. Subcutaneous administration of superoxide dismutase entrapped in long circulating liposomes: in vivo fate and therapeutic activity in an inflammation model. Pharm Res. 2000;17(5):600-6.
68. Cai S, Yang Q, Bagby TR, Forrest ML. Lymphatic drug delivery using engineered liposomes and solid lipid nanoparticles. Adv Drug Deliv Rev. 2011;63:901-8.
69. Wilson B, Samanta MK, Santhi K, Kumar KP, Ramasamy M, Suresh B. Chitosan nanoparticles as a new delivery system for the anti-Alzheimer drug tacrine. Nanomedicine: Nanotechnology, Biology and Medicine. 2010;6(1):144-52.
70. Alhareth K, Vauthier C, Bourasset F, Gueutin C, Ponchel G, Moussa F. Conformation of surfacedecorating dextran chains affects the pharmacokinetics and biodistribution of doxorubicin-loaded nanoparticles. Eur J Pharm Biopharm. 2012.
71. Li M, Panagi Z, Avgoustakis K, Reineke J. Physiologically based pharmacokinetic modeling of PLGA nanoparticles with varied mPEG content. Int J Nanomedicine. 2012;7:1345.
72. Li Y, Wei P, Li J, Li L. Pharmacokinetic analysis and optimization of hydroxycamptothecin-loaded nanoparticles for liver targeting. Drug Dev Ind Pharm. 2011 (00):1-11.
73. Ernsting MJ, Tang WL, MacCallum NW, Li SD. Preclinical pharmacokinetic, biodistribution, and anti-cancer efficacy studies of a docetaxel-carboxymethylcellulose nanoparticle in mouse models. Biomaterials. 2012;33(5):1445-54.
74. Cole AJ, David AE, Wang J, Galbán CJ, Yang VC. Magnetic brain tumor targeting and biodistribution of long-circulating PEG-modified, cross-linked starch-coated iron oxide nanoparticles. Biomaterials. 2011;32(26):6291-301.
75. Tiwari R, Pathak K. Nanostructured lipid carrier versus solid lipid nanoparticles of simvastatin: Comparative analysis of characteristics, pharmacokinetics and tissue uptake. Int J Pharm. 2011;415(1-2):232-43.
76. 4 nanoparticles in mice. Int J Nanomedicine. 2010;5:861.
77. Romero EL, Morilla MJ, Regts J, Koning GA, Scherphof GL. On the mechanism of hepatic transendothelial passage of large liposomes. FEBS Lett. 1999;448(1):193-6.
78. Hobbs SK, Monsky WL, Yuan F, Roberts WG, Griffith L, Torchilin VP, Jain RK. Regulation of transport pathways in tumor vessels: role of tumor type and microenvironment. P N A S. 1998;95(8):4607.
79. Andresen TL, Jensen SS, Jørgensen K. Advanced strategies in liposomal cancer therapy: problems and prospects of active and tumor specific drug release. Prog Lipid Res. 2005;44(1):68-97.
80. Hamaguchi T, Matsumura Y, Suzuki M, Shimizu K, Goda R, Nakamura I, Nakatomi I, Yokoyama M, Kataoka K, Kakizoe T. NK105, a paclitaxel-incorporating micellar nanoparticle formulation, can extend in vivo antitumour activity and reduce the neurotoxicity of paclitaxel. Br J Cancer. 2005;92(7):1240-6.
81. Takino T, Konishi K, Takakura Y, Hashida M. Long circulating emulsion carrier systems for highly lipophilic drugs. Biol Pharm Bull. 1994;17(1):121.
82. Allen TM. Ligand-targeted therapeutics in anticancer therapy. Nat Rev Cancer. 2002;2(10):750-63.
83. Opanasopit P, Sakai M, Nishikawa M, Kawakami S, Yamashita F, Hashida M. Inhibition of liver metastasis by targeting of immunomodulators using mannosylated liposome carriers. J Control Release. 2002;80(1):283-94.
84. Moghimi SM, Porter CJH, Muir IS, Illum L, Davis SS. Non-phagocytic uptake of intravenously injected microspheres in rat spleen: influence of particle size and hydrophilic coating. Biochem Biophys Res Commun. 1991;177(2):861-6.
85. Porter CJH, Moghimi SM, Illum L, Davis SS. The polyoxyethylene/polyoxypropylene block copolymer poloxamer-407 selectively redirects intravenously injected microspheres to sinusoidal endothelial cells of rabbit bone marrow. FEBS Lett. 1992;305(1):62-6.
86. Moghimi SM, Bonnemain B. Subcutaneous and intravenous delivery of diagnostic agents to thelymphatic system: applications in lymphoscintigraphy and indirect lymphography. Adv Drug Deliv Rev. 1999;37(1-3):295-312.
87. Harisinghani MG, Barentsz J, Hahn PF, Deserno WM, Tabatabaei S, van de Kaa CH, de la Rosette J, Weissleder R. Noninvasive detection of clinically occult lymph-node metastases in prostate cancer. N Engl J Med. 2003;348(25):2491-9.
88. Singh R, Pantarotto D, Lacerda L, Pastorin G, Klumpp C, Prato M, Bianco A, Kostarelos K, Tissue biodistribution and blood clearance rates of intravenously administered carbon nanotube radiotracers. Proc Natl Acad Sci U S A. 2006;103(9):3357-62.
89. Roberts JC, Bhalgat MK, Zera RT. Preliminary biological evaluation of polyamidoamine (PAMAM) StarburstTM dendrimers. J Biomed Mater Res. 1996;30(1):53-65.
90. Chen CC, Tsai TH, Huang ZR, Fang JY. Effects of lipophilic emulsifiers on the oral administration of lovastatin from nanostructured lipid carriers: physicochemical characterization and pharmacokinetics. Eur J Pharm Biopharm. 2010;74(3):474-82.
91. Simovic S, Hui H, Song Y, Davey AK, Rades T, Prestidge CA. An oral delivery system for indomethicin engineered from cationic lipid emulsions and silica nanoparticles. J Control Release. 2010;143(3):367-73.
92. Hu LD, Jia H, Luo ZL, Liu C, Xing QB. Improvement of digoxin oral absorption in rabbits by incorporation into solid lipid nanoparticles. Die Pharmazie. 2010;65(2):110-3.
93. Mittal G, Kumar MNV. Impact of polymeric nanoparticles on oral pharmacokinetics: A dose-dependent case study with estradiol. J Pharm Sci. 2009;98(10):3730-4.
94. Hillyer JF, Albrecht RM. Gastrointestinal persorption and tissue distribution of differently sized colloidal gold nanoparticles. J Pharm Sci. 2001;90(12):1927-36.
95. Jia L, Shen J, Zhang D, Duan C, Liu G, Zheng D, Tian X, Liu Y, Zhang Q, In vitro and in vivo evaluation of oridonin-loaded long circulating nanostructured lipid carriers. Int J Biol Macromol. 2012;50(3):523-9.
96. Milane L, Duan ZF, Amiji M. Pharmacokinetics and biodistribution of lonidamine/paclitaxel loaded, EGFR-targeted nanoparticles in an orthotopic animal model of multi-drug resistant breast cancer. Nanomedicine. 2011;7(4):435.
97. Lovrić J, Bazzi HS, Cuie Y, Fortin GRA, Winnik FM, Maysinger D. Differences in subcellular distribution and toxicity of green and red emitting CdTe quantum dots. J Mol Med. 2005;83(5):377-85.
98. Larson DR, Zipfel WR, Williams RM, Clark SW, Bruchez MP, Wise FW, Web WW, Water-soluble quantum dots for multiphoton fluorescence imaging in vivo. Science. 2003;300(5624):1434-6.
99. Ballou B, Lagerholm BC, Ernst LA, Bruchez MP, Waggoner AS. Noninvasive imaging of quantum dots in mice. Bioconjug Chem. 2004;15(1):79-86.
100. Hoshino A, Fujioka K, Oku T, Suga M, Sasaki YF, Ohta T, Yasuhara M, Suzuki K, Yamamoto K, Physicochemical properties and cellular toxicity of nanocrystal quantum dots depend on their surface modification. Nano Lett. 2004;4(11):2163-9.
101. Kawakami S, Opanasopit P, Yokoyama M, Chansri N, Yamamoto T, Okano T, Yamashita F, Hashida M, Biodistribution characteristics of all-trans retinoic acid incorporated in liposomes and polymeric micelles following intravenous administration. J Pharm Sci. 2005;94(12):2606-15.
102. Yu B, Tai HC, Xue W, Lee LJ, Lee RJ. Receptor-targeted nanocarriers for therapeutic delivery to cancer. Mol Membr Biol. 2010;27(7):286-98.
103. Ruoslahti E, Bhatia SN, Sailor MJ. Targeting of drugs and nanoparticles to tumors. J Cell Biol. 2010;188(6):759-68.
104. Li X, Tian X, Zhang J, Zhao X, Chen X, Jiang Y, Wang D, Pan W. In vitro and in vivo evaluation of folate receptor-targeting amphiphilic copolymer-modified liposomes loaded with docetaxel. Int J Nanomedicine. 2011;6:1167.
105. 3H dendrimer nanoparticle organ/tumor distribution. Pharm Res. 2004;21(3):476-83.
106. De Jesús OLP, Henrik R, Gagne L, Fréchet JMJ, Szoka Jr FC. Polyester dendritic systems for drug delivery applications: in vitro and in vivo evaluation. Bioconjug Chem. 2002;13(3):453-61.
107. Allen TM, Chonn A. Large unilamellar liposomes with low uptake into the reticuloendothelial system. FEBS Lett. 1987;223(1):42-6.
108. Webb MS, Harasym TO, Masin D, Bally MB, Mayer LD. Sphingomyelin-cholesterol liposomes significantly enhance the pharmacokinetic and therapeutic properties of vincristine in murine and human tumour models. Br J Cancer. 1995;72(4):896.
109. Klibanov AL, Maruyama K, Torchilin VP, Huang L. Amphipathic polyethyleneglycols effectively prolong the circulation time of liposomes. FEBS Lett. 1990;268(1):235-7.
110. Kawakami S, Wong J, Sato A, Hattori Y, Yamashita F, Hashida M. Biodistribution characteristics of mannosylated, fucosylated, and galactosylated liposomes in mice. Biochim Biophys Acta. 2000;1524(2-3):258-65.
111. Kawakami S, Munakata C, Fumoto S, Yamashita F, Hashida M. Targeted delivery of prostaglandin E1 to hepatocytes using galactosylated liposomes. J Drug Deliv. 2000;8(3):137-42.
112. Kawakami S, Sato A, Nishikawa M, Yamashita F, Hashida M. Mannose receptor-mediated gene transfer into macrophages using novel mannosylated cationic liposomes. Gene Ther. 2000;7(4):292.
113. Gabizon AA. Pegylated liposomal doxorubicin: metamorphosis of an old drug into a new form of chemotherapy. Cancer Invest. 2001;19(4):424-36.
114. Oberdörster G, Sharp Z, Atudorei V, Elder A, Gelein R, Lunts A, Kreyling W, Cox C, Extrapulmonary translocation of ultrafine carbon particles following whole-body inhalation exposure of rats. J Toxicol Environ Health A. 2002;65(20):1531-43.
115. Kreyling WG, Semmler M, Erbe F, Mayer P, Takenaka S, Schulz H, Oberdörster G, Ziesenis A, Translocation of ultrafine insoluble iridium particles from lung epithelium to extrapulmonary organs is size dependent but very low. J Toxicol Environ Health A. 2002;65(20):1513-30.
116. Agarwal A, Lariya N, Saraogi G, Dubey N, Agrawal H, Agrawal GP. Nanoparticles as novel carrier for brain delivery: a review. Curr Pharm Des. 2009;15(8):917-25.
117. Kusuhara H, Sugiyama Y. Efflux transport systems for drugs at the blood-brain barrier and blood-cerebrospinal fluid barrier (Part 1). Drug Discov Today. 2001;6(3):150-6.
118. Gabathuler R. Approaches to transport therapeutic drugs across the blood-brain barrier to treat brain diseases. Neurobiol Dis. 2010;37(1):48-57.
119. Kreuter J. Nanoparticulate systems for brain delivery of drugs. Adv Drug Deliv Rev. 2001;47(1): 65-81.
120. Kreuter J, Alyautdin RN, Kharkevich DA, Ivanov AA. Passage of peptides through the blood-brain barrier with colloidal polymer particles (nanoparticles). Brain Res. 1995;674(1):171-4.
121. Gao K, Jiang X. Influence of particle size on transport of methotrexate across blood brain barrier by polysorbate 80-coated polybutylcyanoacrylate nanoparticles. Int J Pharm. 2006;310(1):213-9.
122. Tsuchiya T, Oguri I, Yamakoshi YN, Miyata N. Novel harmful effects of [60] fullerene on mouse embryos in vitro and in vivo. FEBS Lett. 1996;393(1):139-45.
123. Bosman SJ, Nieto SP, Patton WC, Jacobson JD, Corselli JU, Chan PJ. Development of mammalian embryos exposed to mixed-size nanoparticles. Clin Exp Obstet Gynecol. 2005;32(4):222-4.
124. Loughrey HC, Bally MB, Reinish LW, Cullis PR. The binding of phosphatidylglycerol liposomes to rat platelets is mediated by complement. Thromb Haemost. 1990;64(1):172.
125. Kreuter J, Ramge P, Petrov V, Hamm S, Gelperina SE, Engelhardt B, Alyautdin R, von Briesen H, Begley DJ, Direct evidence that polysorbate-80-coated poly (butylcyanoacrylate) nanoparticles deliver drugs to the CNS via specific mechanisms requiring prior binding of drug to the nanoparticles. Pharm Res. 2003;20(3):409-16.
126. Yan X, Kuipers F, Havekes LM, Havinga R, Dontje B, Poelstra K, Scherphof GL, Kamps JAAM, The role of apolipoprotein E in the elimination of liposomes from blood by hepatocytes in the mouse. Biochem Biophys Res Commun. 2005;328(1):57-62.
127. Owens DE, Peppas NA. Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles. Int J Pharm. 2006;307(1):93-102.
128. Hunter AC, Moghimi SM. Therapeutic synthetic polymers: a game of Russian roulette? Drug Discov Today. 2002;7(19):998-1001.
129. Nagayama S, Ogawara K, Fukuoka Y, Higaki K, Kimura T. Time-dependent changes in opsonin amount associated on nanoparticles alter their hepatic uptake characteristics. Int J Pharm. 2007;342(1-2):215-21.
130. Fang C, Shi B, Pei Y, Hong M, Wu J, Chen H. In vivo tumor targeting of tumor necrosis factor-R-loaded stealth nanoparticles: Effect of MePEG molecularweight and particle size. Eur J Pharm Sci. 2006;27:27-36.
131. Alexis F, Pridgen E, Molnar LK, Farokhzad OC. Factors affecting the clearance and biodistribution of polymeric nanoparticles. Mol Pharm. 2008;5(4):505-15.
132. Farokhzad OC, Langer R. Nanomedicine: developing smarter therapeutic and diagnostic modalities. Adv Drug Deliv Rev. 2006;58(14):1456-9.
133. Jaeghere F, Allemann E, Feijen J, Kissel T, Doelker E, Gurny R. Cellular uptake of PEO surfacemodified nanoparticles: evaluation of nanoparticles made of PLA: PEO diblock and triblock copolymers. J Drug Deliv. 2000;8(3):143-53.
134. Zambaux MF, Faivre-Fiorina B, Bonneaux F, Marchal S, Merlin JL, Dellacherie E, Labrude P, Vigneron C, Involvement of neutrophilic granulocytes in the uptake of biodegradable non-stealth and stealth nanoparticles in guinea pig. Biomaterials. 2000;21(10):975-80.
135. Bazile D, Prud'homme C, Bassoullet MT, Marlard M, Spenlehauer G, Veillard M. Stealth Me. PEG-PLA nanoparticles avoid uptake by the mononuclear phagocytes system. J Pharm Sci. 1995;84(4):493-8.
136. Coyle P, Philcox JC, Carey LC, Rofe AM. Metallothionein: the multipurpose protein. Cell Mol Life Sci. 2002;59(4):627-47.
137. Rajagopalan P, Wudl F, Schinazi RF, Boudinot FD. Pharmacokinetics of a water-soluble fullerene in rats. Antimicrobial agents and chemotherapy. 1996;40(10):2262-5.
138. Cagle DW, Kennel SJ, Mirzadeh S, Alford JM, Wilson LJ. In vivo studies of fullerene-based materials using endohedral metallofullerene radiotracers. P N A S. 1999;96(9):5182.
139. Sayes CM, Fortner JD, Guo W, Lyon D, Boyd AM, Ausman KD, Tao YJ, Sitharaman B, Wilson LJ, Hughes JB, The differential cytotoxicity of water-soluble fullerenes. Nano Lett. 2004;4(10):1881-7.
140. Furumoto K, Ogawara K, Yoshida M, Takakura Y, Hashida M, Higaki K, Kimura T, Biliary excretion of polystyrene microspheres depends on the type of receptor-mediated uptake in rat liver. Biochim Biophys Acta. 2001;1526(2):221-6.
141. Ogawara K, Yoshida M, Higaki K, Kimura T, Shiraishi K, Nishikawa M, Takakura Y, Hashida M, Hepatic uptake of polystyrene microspheres in rats: effect of particle size on intrahepatic distribution. J Control Release. 1999;59(1):15-22.
142. 60 (OH) x and its biodistribution studies. Nucl Med Biol. 2002;29(6):707-10.